Dejan Micic to Gastrointestinal Agents
This is a "connection" page, showing publications Dejan Micic has written about Gastrointestinal Agents.
Connection Strength
0.990
-
Long-Term Outcomes With Teduglutide From a Single Center. JPEN J Parenter Enteral Nutr. 2021 02; 45(2):318-322.
Score: 0.653
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.154
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.142
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.041